

A SUPPLEMENT TO

JOURNAL OF DRUGS IN DERMATOLOGY

JDD

DRUGS • DEVICES • METHODS

Advanced Basal Cell Carcinoma:  
Therapeutic Options and Considerations  
for Patient Care

CME Supplement



Take the Online  
CME Test Now for  
Instant Results!



ISSN: 1545 9616

October 2013 • Volume 12 • Issue 10 (SUPPLEMENT)

© 2013 Journal of Drugs in Dermatology. All Rights Reserved.

This document contains proprietary information, images and marks of Journal of Drugs in Dermatology (JDD).  
No reproduction or use of any portion of the contents of these materials may be made without the express written consent of JDD.  
If you feel you have obtained this copy illegally, please contact JDD immediately.

JO1013

### **Disclosure of Commercial Support**

This CME activity has been supported by an educational grant from Genentech.

This supplement to the *Journal of Drugs in Dermatology* is supported by Genentech, Copyright © 2013, and published by the *Journal of Drugs in Dermatology*. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the publisher. The opinions or views expressed in this professional educational supplement are those of the authors and do not reflect the opinions or recommendations of Genentech or the *Journal of Drugs in Dermatology*.



## CME

- s144 **CME**
- s156 **CME Post-Test**
- s157 **CME Evaluation/Certificate Request Form**

## EDITORIAL

- s146 **Introduction**  
*Kenneth R. Beer MD FAAD and Michael S. Beer*

## ORIGINAL ARTICLES

- s147 **Treatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications**  
*Stephanie Bayers BSBA, Daniel L. Kapp MD FACS, Kenneth R. Beer MD FAAD, and Benjamin Slavin*
- s151 **The Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical, and Psychological Burden of the Disease**  
*Arielle W. Haves BA, Panta Rouhani Schaffer MD PhD MPH, and John A. Carucci MD PhD*
- s154 **Vismodegib: A Hedgehog Pathway Inhibitor for Locally Advanced and Metastatic Basal Cell Carcinomas**  
*Joesph F. Sobanko MD, Jonathan Okman BA MBA, and Christopher Miller MD*

## ADVANCED BASAL CELL CARCINOMA: THERAPEUTIC OPTIONS AND CONSIDERATIONS FOR PATIENT CARE

Original Release Date: October 1, 2013

Most Recent Review Date: September 1, 2013

Termination Date: September 30, 2014

Estimated Time to Complete This CME Activity: 1 hour

Medium or Combination of Media Used: Written supplement

Method of Physical Participation: Journal article, web-based post-test, and evaluation

Hardware/Software Requirements: High speed internet connection

**Statement of Need**

The standard of care for non-melanoma skin cancers (NMSC), including the advanced stages of basal cell carcinoma (BCC), are currently surgery and radiation. However, if the tumor is located where such treatment may cause significant change in appearance or loss of function, or if it reoccurs after traditional therapy, these treatments prove ineffective or are not an option. This leaves the dermatologist with few viable options to manage the disease, and presents a challenge for improving patient quality of life and general health.

Recently there has been increased research into treatment options for NMSCs that reports on the advanced understanding of their genetics. This has led to increased interest in the role of the sonic hedgehog (Hh) pathway, its role in the pathogenesis of advanced BCC, and a new oral inhibitor of the Hh pathway as a systemic treatment for patients not amenable to surgery or radiation. This supplement will educate dermatologists about advanced BCC, including the signs, symptoms and early detection, patient classification, epidemiology, limitations of current treatment regimens, and emerging new treatments. By drawing on research from recently published literature, as well as clinical evidence and perspectives of leading experts from the discipline of dermatology and dermatologic surgery/oncology, it presents the most current information on new targeted treatment strategies, including inhibition of the Hh signaling pathway for the treatment of locally advanced BCC.

**Educational Objectives**

This activity is a multi-specialty, evidence-based initiative designed to increase the knowledge and competence of dermatological practitioners by providing them with the simultaneous integration of knowledge, skills, and judgment from thought-leader testimonials, science-based research, and evidence-based data to address the difference between present patient outcomes and those considered achievable in the field of dermatology.

Upon completion of this activity, participants should be able to:

1. Recognize the impact of inoperable advanced BCC, including the economic, physical, and psychological burden of the disease
2. Differentiate disease characteristics and diagnostic markers to better identify patients with advanced BCC

3. Discuss the mechanism of action of vismodegib and the role of Hh pathway inhibition in the management of advanced BCC
4. Evaluate data from recent clinical trials and published literature on the use of biologic response modifiers in the treatment of advanced BCC
5. Integrate innovative treatment plans for patients with positive margin BCC whenever appropriate

**Target Audience**

This activity is intended for dermatologists, residents in dermatology, and physician assistants who need continued education for understanding when vismodegib is applicable and when it is not, how the drug works, and which adverse events are associated with it.

**Accreditation Statement**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville and Physicians Continuing Education Corporation. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

**Credit Designation**

The University of Louisville Continuing Medical Education designates this enduring material for a maximum of one (1.0) *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in this activity.

**How to Obtain CME Credit**

You can earn one (1.0) *AMA PRA Category 1 Credit*<sup>™</sup> by reading the 3 articles contained in this supplement and completing a web-based post-test and evaluation.

Test is valid through September 30, 2014 (no credit will be given after this date).



To receive credit for this activity, please go to [www.JDDonline.com](http://www.JDDonline.com) and click on CME Activities under "Library." You will find instructions for taking the post-test and completing the program evaluation. You must earn a passing score of at least 70% and complete and submit the activity evaluation form in order to receive a certificate for an *AMA PRA Category 1 Credit*™. There is no fee for this CME activity. Once you have completed the form online, you will be able to print your certificate directly. You can also receive credit for this activity by completing the post-test and evaluation at the end of this supplement and faxing or mailing it to JDD, 377 Park Avenue South, 6th Floor, NY, NY 10016; fax: (718) 407-0898.

### Faculty Credentials

Kenneth R. Beer MD FAAD (Palm Beach Plastic Surgery Center, West Palm Beach, FL), Michael S. Beer (Personal Assistant to Kenneth Beer MD), Stephanie Bayers BSBA (University of Miami Miller School of Medicine, Miami, FL), Daniel L. Kapp MD FACS (Palm Beach Plastic Surgery Center, West Palm Beach, FL), Benjamin Slavin (University of Miami, Miami, FL), Arielle W. Haves BA (Ronald O. Perelman Department of Dermatology, New York University, New York, NY), Panta Rouhani Schaffer MD PhD MPH (Ronald O. Perelman Department of Dermatology, New York University, New York, NY), John A. Carucci MD PhD (Ronald O. Perelman Department of Dermatology, New York University, New York, NY), Joesph F. Sobanko MD (Division of Dermatologic Surgery and Cutaneous Oncology, University of Pennsylvania, Philadelphia, PA), Jonathan Okman BA MBA (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA), and Christopher Miller MD (Division of Dermatologic Surgery and Cutaneous Oncology, University of Pennsylvania, Philadelphia, PA).

### Disclosures

Policy on Faculty and Provider Disclosure: It is the policy of the University of Louisville to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Louisville are required to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed.

Any real or apparent conflicts of interest have been addressed through a peer review process, as required by ACCME.

The faculty/authors have the following disclosed conflicts of interest: Kenneth Beer MD FAAD receives fees from Genentech for speaking and research. John A. Carucci MD PhD has served as an advisory board participant and clinical investigator for Genentech, Novartis, and Pfizer. Arielle W. Haves BA, Panta Rouhani Schaffer MD PhD MPH, Stephanie Bayers BSBA, Daniel Kapp MD FACS, Benjamin Slavin, Joesph F. Sobanko MD, Jonathan Okman BA MBA, and Christopher Miller MD have no conflicts of interest to disclose.

The peer reviewers have no relevant conflicts of interest to disclose.

The planning committee of this activity, Nick Gillespie (Assistant Publisher JDD), Lucy James (Project Manager JDD Supplements), and Kenneth R. Beer MD FAAD (Palm Beach Plastic Surgery Center, West Palm Beach, FL), have no relevant conflicts of interest to disclose.

**Disclosure of Unlabeled Use:** This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. FDA. The University of Louisville, *Journal of Drugs in Dermatology*, and the activity supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Louisville, the *Journal of Drugs in Dermatology*, and the activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclosure of Commercial Support:** This supplement to the *Journal of Drugs in Dermatology* has been made possible by an unrestricted educational grant from Genentech.

### Special Services

If you need special accommodations due to a disability, or require an alternative form of course materials, e-mail Nick Gillespie at [Nick.Gillespie@jddonline.com](mailto:Nick.Gillespie@jddonline.com). The *Journal of Drugs in Dermatology* is committed to providing whatever special assistance its users require to complete this educational activity.

### Contact Information

If you need technical support or have questions about the course, please e-mail Nick.Gillespie@jddonline.com.

For questions about the Internet CME activity content, please contact University of Louisville Continuing Medical Education at [cmepd@louisville.edu](mailto:cmepd@louisville.edu).

### University of Louisville CME & PD Privacy Policy

All information provided by course participants is confidential and will not be shared with any other parties for any reason without permission.

### Copyright

All of the content in this educational activity is copyrighted by the *Journal of Drugs in Dermatology*. The University of Louisville has obtained permission from the *Journal of Drugs in Dermatology* to use the content in this educational activity.

# Introduction



Kenneth R. Beer MD FAAD

The treatment of basal cell carcinoma (BCC) has remained largely unchanged for the past 50 years. Recently, the use of immunomodulators such as imiquimod have been used to treat early lesions. However, the treatment of inoperable BCC did not evolve significantly until the advent of vismodegib. This drug inhibits the hedgehog pathway, which is often defective in BCC, and the United States Food and Drug Administration has approved vismodegib to treat BCC that is locally advanced or metastatic. The use of this drug requires physicians to have an understanding of where it is and where it is not applicable, how the drug works, and which adverse events are associated with it. This supplement details one case of locally advanced BCC and provides information on the therapeutic decisions made for the patient detailed. In addition, information about the mechanisms of action for vismodegib and the burden of disease imposed by advanced or metastatic BCC are provided to help clinicians gain an understanding of the true burden of this disease.

**Kenneth R. Beer MD FAAD<sup>a</sup> and Michael S. Beer**

*<sup>a</sup>Palm Beach Plastic Surgery Center  
West Palm Beach, FL*

# Treatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications

Stephanie Bayers BSBA,<sup>a</sup> Daniel L. Kapp MD FACS,<sup>b</sup>  
Kenneth R. Beer MD FAAD,<sup>b</sup> and Benjamin Slavin<sup>c</sup>

<sup>a</sup>University of Miami Miller School of Medicine, Miami, FL

<sup>b</sup>Palm Beach Plastic Surgery Center, West Palm Beach, FL

<sup>c</sup>University of Miami, Miami, FL

## ABSTRACT

Historically, basal cell carcinomas (BCCs) that are neither surgically resectable nor candidates for radiation therapy have had few treatment options. The hedgehog pathway inhibitor, vismodegib, represents a new opportunity for the treatment of such patients. Vismodegib has approval from the United States Food and Drug Administration for treatment of metastatic BCC, locally advanced BCC recurring after surgery, and BCC that is not treatable via surgery or radiation. We present the case of a patient with a BCC infiltrating the spinal column that was neither possible to fully remove surgically nor a candidate for primary treatment with radiation. Treatment with vismodegib followed by adjuvant radiation therapy resulted in complete disease clearance. Vismodegib represents a promising treatment option for patients with surgically non-resectable BCCs that are not candidates for radiation therapy. Mechanism of action, benefits, and adverse events of vismodegib are reviewed, along with a brief discussion on newer options in the hedgehog inhibitor class.

*J Drugs Dermatol.* 2013;12(suppl 10):s147-s150.

## INTRODUCTION

**B**asal cell carcinoma (BCC) is frequently associated with mutations in the *PTCH* gene leading to dysregulation of the hedgehog (Hh) pathway.<sup>1,3</sup> This mutation is seen in more than 90% of BCCs and causes uninhibited tumor growth. Fortunately, the majority of BCCs are easily treated with a variety of modalities including surgery (electrodesiccation and curettage, Mohs), radiation, topical immunomodulation, and cryosurgery. However, for some patients, the removal of a BCC, either using Mohs micrographic surgery or intraoperative frozen sections, may not result in clear pathologic margins. For these patients, subsequent treatment is not standardized, but options usually include additional Mohs, radiation, or, for those unable to undergo further surgery or radiation, topical 5-fluorouracil, topical imiquimod, photodynamic therapy, or cryotherapy.<sup>4-7</sup> Lesions that are surgically non-resectable due to their proximity to vital structures or the risk of cosmetic deformation may also not be subject to radiation therapy. Moreover, when surgical extirpation of BCCs is aborted because of their proximity to adjacent sensitive structures, such as peripheral motor nerves or the central nervous system, the possibility of adjunctive radiation therapy is often ruled out too. Until recently, traditional chemotherapy has been ineffective for the treatment of BCCs, and patients with non-resectable BCC have had few treatment options. However, the advent of vismodegib (Erivedge®; Genentech) presents an opportunity to treat patients with partially resected disease.

This population of patients represents an unmet need with historically few treatment options. In this report, we discuss one patient treated with vismodegib following positive surgical margins. In addition to a discussion of vismodegib, therapeutic choices available to control BCC postoperatively when positive margins are obtained will also be discussed.

## Case Report


A 69 year-old man presented to his primary care physician with a large lesion on his back (Figure 1). According to the patient, the lesion had been there for more than 10 years and was not causing him any discomfort. He had been caring for the lesion at home with simple dry dressing changes. However, when it began to bleed on a consistent basis, he sought care from his primary care physician. The patient was ultimately admitted to the hospital for evaluation and management of the lesion.

Examination at presentation revealed a 24 cm x 30 cm lesion on his middle back. There was adhesion to the underlying structures with a friable, hypergranulated surface. Computed tomography (CT) scans revealed a large lesion extending from T5 to T11 that measured approximately 17 cm (Figure 2). A surgical biopsy demonstrated an infiltrative BCC (Figure 3). Based on the physical examination, it was decided that resection of the lesion would be the optimal treatment approach.

**FIGURE 1.** Preoperative presentation of the basal cell, which spans the entire width of the patient's back. The surface is friable and bleeding.



**FIGURE 3.** Pathologic evaluation of a biopsy revealed an infiltrative basal cell carcinoma.




Alternatives to surgery, including radiation and topical imiquimod, were considered. Given the extensive size of the tumor and the dose of radiation required with proximity to the spinal cord, radiation would pose significant risk to the central nervous system. Topical imiquimod was considered inappropriate because it would likely be ineffective for such a deep tumor.


During surgery, it became apparent that the size and depth of the tumor were substantially greater than initially appreciated via CT scan and that the tumor had infiltrated into the spinous processes of multiple vertebrae (Figure 4). Alternatives for treatment included complete resection of the affected spinous processes or termination of the surgical procedure. Because of the length of the procedure and the involvement of multiple vertebral levels, it was elected to terminate the resection and reconstruct the defect using left and right paraspinous muscle flaps as well as right and left latissimus dorsi flaps. A second stage operation was performed for skin graft closure over the muscles.

The patient had an uneventful recovery and his surgical site healed without any complications. Treatment options for the patient were discussed based on the depth and location of the

**FIGURE 2.** Computed tomography scan obtained prior to surgery demonstrates the depth and span of the lesion. The size of the lesion fulfills criteria for use of oral treatment with vismodegib.



**FIGURE 4.** Intraoperative examination of the depth and breadth of the lesion. Clear surgical margins were not achievable.



tumor. These included radiation, observation, additional surgery with neurosurgical participation, or treatment with an oral Hh inhibitor, such as vismodegib.

After consultation with an oncologist and a dermatologic surgeon, it was decided to initiate treatment with vismodegib at 150 mg per day.

After using vismodegib for approximately 3 months, the patient elected to discontinue this treatment due to adverse events (AEs), primarily lethargy and dysgeusia. He was subsequently evaluated by radiation oncology and treated with radiation; the risk of radiation injury to the spinal column at this point was determined to be less than the risk of leaving the remaining



BCC untreated. At the time of publication, 6 months after this course of treatment, there is no evidence of disease. As with other high-risk patients, he will be monitored closely.

"Vismodegib represents a promising treatment option for patients with surgically non-resectable basal cell carcinomas that are not candidates for radiation therapy."

## DISCUSSION

There are significant issues in the treatment of partially resected BCCs, the most salient of which has been the lack of treatment options for patients with BCCs located near vital structures. Patients with large BCCs are a second category of patient for whom treatment options have been suboptimal to date. One consideration when considering treatment options for patients with positive margins is the fact that approximately one-third of these patients are subsequently found to have no residual tumor when repeat surgery is performed.<sup>8</sup> Fortunately, other treatment options exist, such as topical 5-fluorouracil, topical imiquimod, photodynamic therapy, or cryotherapy.<sup>4-7</sup> However, these options are not sufficient for locally advanced or metastatic BCCs. In January 2012, the United States Food and Drug Administration (FDA) approved vismodegib for the treatment of metastatic BCC or locally advanced BCC that has recurred after surgery, as well as for patients who are not candidates for surgery or radiation.

Patched homologue 1 (PTCH1) normally functions to inhibit smoothened (SMO) signaling. Without this inhibition, SMO induces transcription factors in basal cells that promote cell proliferation and growth. Hedgehog is key in the development of BCC by inhibiting PTCH1, and thus eliminating the inhibition of SMO, ultimately resulting in cell proliferation.<sup>9,10</sup> Basal cell carcinomas most often result from loss of function mutations in PTCH1, but may also arise from activating mutations in SMO. The significance of vismodegib to BCC is in its ability to bind to and inhibit SMO, thereby bringing about crucial inhibition of basal cell proliferation regardless of whether the mutation is in PTCH1 or SMO.

In a phase 1 study to assess the safety and tolerability of vismodegib, 15 patients with locally advanced basal tumors, as with our patient, were enrolled. Two of these patients demonstrated complete clinical response, 7 showed partial response, 4 had stable disease, and 2 had progressive disease. In those who responded, median duration of response was 8.8 months.<sup>9</sup> A phase 2 study to further assess efficacy and safety showed complete response in 13 patients (21%) with locally advanced

BCC with a median duration of response of 7.6 months and median progression-free survival of 9.5 to 1.3 months.<sup>3</sup>

Adverse events identified during these studies included fatigue, muscle spasms, alopecia, dysgeusia, weight loss, anorexia, dyspnea, nausea, diarrhea, arthralgias, vomiting, and constipation. Three of 10 premenopausal women developed amenorrhea. Hyponatremia, azotemia, and hypokalemia were the most serious laboratory anomalies that arose. Rare events included atrial fibrillation, dyspepsia, aspiration, back pain, corneal abrasion, dehydration, keratitis, lymphopenia, pneumonia, urinary tract infection, prolonged QT interval, cholestasis, pulmonary embolism, dehydration and/or syncope, hypocalcemia, elevated alkaline phosphatase, and hyperkalemia; most of these developed in no more than one patient.<sup>3,9,11-13</sup> All patients in the phase 2 trial experienced at least one AE.<sup>3</sup>

While the most common side effects are generally considered to be minor-to-moderate in severity, they can be unbearable for some patients. Their high frequency has resulted in many patients opting to discontinue the medication, a very unfortunate dilemma for patients in need of vismodegib as a therapeutic option. Another concern and potential limitation of vismodegib is the potential for resistance as well as a recurrence of BCC once the medication is discontinued. In one retrospective review, 21% of patients with advanced BCC experienced tumor regrowth while still on vismodegib treatment.<sup>14</sup>

Future options for these difficult to treat advanced BCCs are under study. Several inhibitors of GLI, a transcription factor downstream of SMO, have been identified.<sup>10,15,16</sup> The antifungal itraconazole is also a Hh inhibitor and is under investigation for its applicability to BCC treatment, potentially in combination with arsenic trioxide.<sup>10</sup> While the common AEs associated with vismodegib are thought to be a class effect of Hh inhibitors, it remains to be seen whether or not the side effects with these newer therapeutic options will be as significant or as unpleasant for patients, and how their efficacy compares to that of vismodegib.

## CONCLUSION

The patient presented represents an unusual and instructive case because he presented with easily monitored disease, but no traditional treatment alternatives seemed to offer promise for disease control. The proximity of his tumor to his spinal cord mandated that some type of treatment be instituted to protect his central nervous system.

Patients with partially treated BCCs often present with similar circumstances to the patient presented in this report: they may have had Mohs surgery or other margin-controlled surgery that was not successful because of anatomic boundaries that could

not be breached. Metastatic BCC and BCCs that cannot be resected are rare. Whereas some of these non-resectable patients may be treated with radiation, many are not candidates for this modality due to proximity to vital structures. For these patients, vismodegib offers a valuable alternative for treatment.

## DISCLOSURES

Kenneth Beer MD FAAD receives fees from Genentech for speaking and research. Stephanie Bayers BSBA, Daniel Kapp MD FACS, and Benjamin Slavin have no conflicts of interest to disclose.

## REFERENCES

1. Undén AB, Zaphiropoulos PG, Bruce K, Toftgård R, Ståhle-Bäckdahl M. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. *Cancer Res.* 1997;57(12):2336-2340.
2. Marigo V, Davey RA, Zuo Y, Cunningham JM, Tabin CJ. Biochemical evidence that patched is the Hedgehog receptor. *Nature.* 1996;384(6605):176-179.
3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med.* 2012;366(23):2171-2179.
4. Halen ML, Ratner D, Patel A. Basal Cell Carcinoma. In: Alam M, ed. *Evidence-Based Procedural Dermatology*. New York: Springer Science + Business Media; 2012:38-39.
5. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. *Arch Dermatol.* 1999;135(10):1177-1183.
6. National Comprehensive Cancer Network®. NCCN Guidelines®: Basal Cell and Squamous Cell Skin Cancers. 2012. [http://www.nccn.org/professionals/physician\\_gls/pdf/nmsc.pdf](http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf). Accessed August 26 2013.
7. Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. *Semin Cutan Med Surg.* 2011;30(suppl 4):s10-s13.
8. Patel SS, Cliff SH, Ward Booth P. Incomplete removal of basal cell carcinoma: what is the value of further surgery? *Oral Maxillofac Surg.* 2013;17(2):115-118.
9. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med.* 2009;361(12):1164-1172.
10. Geeraert P, Williams JS, Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. *J Drugs Dermatol.* 2013;12(5):519-523.
11. Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. *Nat Rev Drug Discov.* 2012;11(6):437-438.
12. Rudin CM. Vismodegib. *Clin Cancer Res.* 2012;18(12):3218-3222.
13. Genentech Inc. Erivedge™ Prescribing Information. 2012. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/203388lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf). Accessed August 26 2013.
14. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. *Arch Dermatol.* 2012;148(11):1324-1325.
15. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. *Proc Natl Acad Sci USA.* 2010;107(30):13432-13437.
16. Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. *Proc Natl Acad Sci USA.* 2007;104(20):8455-8460.

## AUTHOR CORRESPONDENCE

### Kenneth Beer MD FAAD

E-mail:.....kenbeer@aol.com

# The Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical, and Psychological Burden of the Disease

Arielle W. Haves BA, Panta Rouhani Schaffer MD PhD MPH, and John A. Carucci MD PhD

Ronald O. Perelman Department of Dermatology, New York University, New York, NY

## ABSTRACT

The development of vismodegib and its recent approval by the United States Food and Drug Administration for use in patients with locally advanced or metastatic basal cell carcinoma (BCC) carries with it a renewed sense of optimism. Once BCC has progressed to an advanced, or so-called inoperable stage, there has been a paucity of effective therapies, making the new small molecule inhibitors targeting the hedgehog pathway particularly hopeful prospects. In order to better understand the utility of these new treatments, it is important to assess the existing economic, physical, and psychological burden of advanced BCC. This review aims to recognize the impact of inoperable and metastatic BCC, as well as to better characterize the various types of advanced BCC. The use of vismodegib as a prophylactic treatment in patients with basal cell nevus syndrome is also addressed, including possible adverse events, tumor resistance, and new onset malignancies.

*J Drugs Dermatol.* 2013;12(suppl 10):s151-s153.

## INTRODUCTION

While the overwhelming majority of basal cell carcinoma (BCC) is effectively managed with surgery, causing minimal distress to the patient, individuals whose BCC has metastasized or progressed to an inoperable state are severely affected by their disease.<sup>1</sup> The physical disfigurement from advanced lesions as well as concern about life expectancy affect both quality of life (QOL) and the psychological state of the patient.<sup>2</sup> In interviews with clinicians, Shingler et al found that the most common symptom of patients with advanced BCC was embarrassment from either the dressings or the lesions themselves. Metastatic lesions may weep or bleed, have the potential to become infected, and consequently can become malodorous.<sup>2</sup> As a result, patients with advanced BCC may isolate themselves from family, friends, and the workplace, despite the fact that they may be physically able to carry on with the normal activities of daily life. Anxiety and depression can also often accompany this social isolation.<sup>2</sup>

Because BCC metastasis is extremely rare, with a reported incidence of 0.0028% to 0.5%, it is difficult to quantify the economic, physical, and psychological impact of the disease.<sup>3,4</sup> There has been very little in the medical literature that attempts to investigate how and to what extent the QOL is affected in patients with advanced BCC, as case reports only offer qualitative information regarding the burden of the disease. In an attempt to capture social utility values associated with different levels of advanced BCC, Shingler et al employed a newer methodology known as the time trade-off (TTO) measurement.<sup>2</sup> A representative sample of the general public in the United Kingdom was asked to choose between living in a particular health state with advanced BCC for 10 years vs living in a state of full health for

10-x years.<sup>2</sup> The TTO method was used to calculate utility values based upon the responses to these scenarios.<sup>2</sup> The health states of advanced BCC used in the valuation exercise included the following: complete response (CR), post-surgical state, partial response (PR) with small growth, PR with large growth, stable disease (SD) with small growth, SD with multiple growths (at 2 cm), SD with large growth, progressed disease (PD) with small growth, and PD with large growth.<sup>2</sup> Small growth was defined as 2 cm and large growth as 6 cm. While the study was limited in its ability to capture all possible presentations of advanced BCC, several important findings did emerge.

Not unexpectedly, the highest mean utility value, or amount of time participants were willing to trade for a full state of health, was for the complete response state (94%). The lowest utility value was progressed disease with large growth (67%).<sup>2</sup> The size and number of lesions was also found to be an important influence on QOL, and those states were accordingly valued. The most interesting finding of all was that the post-surgical state was valued second to last at 74%.<sup>2</sup> The post-surgical state was found to have even more impact on QOL than progressed disease with small growth, suggesting that the general public perceives the impact of disfigurement from extensive surgery for advanced BCC just as debilitating as the experience of progressed disease. From these data, Shingler et al concluded that patients with larger lesions as well as those with numerous lesions would benefit from non-surgical intervention.<sup>2</sup> Additionally, treatment efforts to reduce the size and number of lesions were also highly valued by patients.

In addition to the physical and psychological impact of advanced BCC, the financial burden of non-melanoma skin cancer

(NMSC) is also significant. As the prevalence of NMSC has globally increased over the past 3 decades, the costs involved in treatment and management have also risen.<sup>5</sup> Between 1992 and 2006, the number of procedures performed for NMSC in the United States rose by 76.9%.<sup>6</sup> Although treatment for an individual case of BCC is low compared with other malignancies (approximately \$492 in a physician's office setting), NMSC ranks fifth for cancer cost in the Medicare population.<sup>6,7</sup> This equates to 4.5% of all Medicare cancer costs.<sup>6,8</sup> The cost of treatment for an episode of BCC is positively correlated with tumor size and anatomical site. Lesions on the head and neck or feet are associated with a higher cost.<sup>6</sup> In 2004, the total direct cost associated with treatment for NMSC was \$1.5 billion.<sup>9</sup>

For patients with multiple BCCs requiring frequent and recurrent treatment, preventative management with a targeted molecular therapy offers promise. Genentech offers a one-month supply of once-daily capsules of vismodegib for \$7,500, which comes out to \$250 per capsule.<sup>9</sup> While the length of treatment may vary by patient, the expected length of therapy is 10 months. This is a conservative estimate since the endpoint for BCC treatment remains undefined. Thereby, the total average cost is \$75,000.<sup>9</sup> This represents a cost increase of 150-fold over the current modalities. The sales projections in Europe are predicted to reach \$401 million by 2015, and peak at \$533 million in 2022.<sup>9</sup>

### **Differentiate Disease Characteristics and Diagnostic Markers to Better Identify Patients With Advanced Basal Cell Carcinoma With the Presence of Basal Nevus Syndrome**

While the majority of BCC cases are found early and effectively cured by surgery and other treatment modalities, the minority that present late can progress to life-threatening, unresectable, advanced BCC, either in the form of locally advanced BCC or metastatic BCC tumors.<sup>2,8</sup> Late presentations and progression to advanced disease can occur due to a variety of factors. The patient may not have sought out timely treatment due to denial or neglect, or perhaps due to lack of finances or access to health care.<sup>5</sup> Psychiatric comorbidities can also play a role in the progression of BCC to advanced disease.<sup>5</sup> The point at which BCC becomes "advanced" or "inoperable" is somewhat subjective, as some physicians may be more willing than others to attempt surgical treatment, based on experience and expertise. Additionally, surgery may be precluded as a treatment modality secondary to patient age or comorbidities. In these situations, a multidisciplinary team comprised of experts in dermatologic surgery, surgical oncology, head and neck oncologic surgery, radiology, medical oncology, and radiation oncology should be considered.<sup>10</sup>

The instances when advanced BCC tumors develop despite aggressive treatment are known as "high risk BCC." These lesions are characterized by several markers hypothesized to be related

to a more aggressive BCC tumor phenotype.<sup>5</sup> Characteristics include long duration, location on central face or ears, diameter greater than 2 cm in size, aggressive histologic subtype, perivascular or perineural spread, a history of radiation exposure, incomplete treatment, or previous treatment failure.<sup>5,11,12</sup> Other reasons, however, for this high risk phenotype are not fully understood at this time.<sup>8</sup>

**"Once basal cell carcinoma has progressed to an advanced, or so-called inoperable stage, there has been a paucity of effective therapies, making the new small molecule inhibitors targeting the hedgehog pathway particularly hopeful prospects."**

While large BCCs are difficult to manage, the size itself does not necessarily deem a BCC "inoperable" or metastatic. In fact, certain BCCs that appear "typical" may very well be recurrences requiring multiple procedures, which, in turn, become inoperable or metastatic. In the past, radiation was the only alternative for these patients. However, there are certain skin conditions in which radiation is contraindicated, such as basal cell nevus syndrome (BCNS) or xeroderma pigmentosum.<sup>8</sup>

Basal cell nevus syndrome is an autosomal dominant disorder characterized by multiple basal cell carcinomas with onset occurring between puberty and 35 years of age.<sup>13</sup> The current prevalence is estimated to be 1/57,000 to 1/256,000.<sup>13</sup> Males and females are equally affected, and the syndrome has been found across multiple ethnicities and geographic locations.<sup>13</sup> The classical clinical triad of BCNS is multiple BCCs, jaw keratocysts, and bifid ribs. Additional clinical features may include craniofacial defects such as macrocephaly, frontal bossing, and coarse facial features, facial milia, downward sloping shoulders, palmar-planar pits, ectopic intracranial calcifications, and central nervous system defects.<sup>12,13</sup> As the syndrome may manifest in a variety of ways, the diagnosis of BCNS is fulfilled with 2 major criteria and 1 minor criterion, or 1 major criterion and 3 minor criteria.

Basal cell nevus syndrome is caused by mutations in the sonic hedgehog (SHh) pathway, with the most common mutation located in the patched homologue 1 (PTCH1) gene, a tumor suppressor gene mapped to chromosome 9q22.3.<sup>13</sup> The SHh pathway, while essential during embryogenesis for cell proliferation and growth, typically becomes inactive during adulthood.<sup>10</sup> Patched homologue 1 is a SHh receptor on the cell membrane that suppresses the activation of another transmembrane protein, smoothened (SMO), a SHh pathway activator.<sup>13</sup> When the



secreted SHh protein binds to its receptor, PTCH1, it activates SMO. Once activated, SMO promotes downstream transcription of target genes and activates other transcription factors in the glioma-associated oncogene (GLI) family, including GLI1 which is specifically involved in cellular proliferation and growth.<sup>8,12</sup> Glioma-associated oncogene 1 serves as a transcription factor for itself, as well as inducing PTCH1 transcription, creating a negative feedback loop.<sup>13</sup> In an individual with BCNS, however, PTCH1 genes are mutated and inappropriately inactivated, leading to unregulated stimulation of the SHh pathway because the PTCH1 protein cannot effectively inhibit SMO. Constitutive activation of SHh causes abnormal cell growth and carcinogenesis, leading to multiple BCCs.<sup>13</sup> In cases of sporadic BCC, not only have loss-of-function mutations in PTCH1 been implicated in 30% to 40% of cases, but also gain-of-function mutations activating SMO are also a possible mechanism as SMO is mutated in about 10% of sporadic BCC cases.<sup>5,11</sup>

Because radiation is contraindicated in BCNS and other genetic syndromes that predispose one to skin cancer, few treatment options remain for these patients. Topical therapy, such as 5-fluorouracil and imiquimod, photodynamic therapy, and cryotherapy, may be used, but they are less effective than the conventional treatments of surgery and radiation.<sup>9</sup> Prior therapies have included chemotherapy (ie, cisplatin-based chemotherapy) as well as molecular targeted therapies (ie, cetuximab).

One of the most recent additions to the armamentarium of therapies for patients with BCNS has been vismodegib (Erivedge®; Genentech). Vismodegib was approved by the United States Food and Drug Administration in January 2012 as the first oral medication for adults with metastatic or locally advanced BCC that has recurred after surgery or for patients who are not candidates for surgery or radiation.<sup>9</sup> This medication is particularly promising as a prophylactic agent because the number of BCCs among patients with BCNS is high, ranging from hundreds to thousands in a single patient.<sup>14</sup> Tang et al studied the use of vismodegib in patients with BCNS and found that the drug significantly reduced existing BCC tumor burden as well as blocked the growth of new BCCs.<sup>14</sup> However, adverse events (AEs), such as dysgeusia, hair loss, muscle cramps, and weight loss, led to discontinuation of over half the patients enrolled in the study.<sup>14</sup> In addition to these AEs, there are recent reports in the literature of patients on vismodegib experiencing secondary (acquired) resistance to treatment, even in patients with BCNS.<sup>15</sup> Chang et al studied 28 patients with advanced BCC on continuous vismodegib therapy and found that 21% developed at least one tumor regrowth.<sup>16</sup> While the molecular mechanism for this acquired resistance is still unclear, it is important to closely monitor patients on vismodegib as this may be an increasing phenomenon that is only beginning to be described.<sup>16</sup> Additionally, there have been reports in the literature of the development of rapid new onset keratoacanthomas (KAs) and

squamous cell carcinomas (SCCs) associated with vismodegib treatment.<sup>17</sup> While KAs and SCCs have previously not been associated with SMO inhibitors, such cases warrant further investigation, especially since hereditary disorders such as BCNS would require long-term therapy. As promising as vismodegib may be, systemic therapy for advanced BCC is not curative, requires long-term treatment, and should not take the place of curative procedures such as surgery.<sup>10</sup>

## DISCLOSURES

John A. Carucci MD PhD has served as an advisory board participant and clinical investigator for Genentech, Novartis, and Pfizer. Arielle W. Haves BA and Panta Rouhani Schaffer MD PhD MPH have no conflicts of interest to disclose.

## REFERENCES

- Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. *Qual Life Res*. 1996;5(2):191-194.
- Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. *J Med Econ*. 2013;16(6):777-783.
- Soleymani AD, Scheinfeld N, Vasil K, Bechtel MA. Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. *J Am Acad Dermatol*. 2008;59(2 suppl 1):s1-s3.
- Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013 Jan 10. [Epub ahead of print.]
- Wollina U, Tchernev G. Advanced basal cell carcinoma. *Wien Med Wochenschr*. 2013 Apr 16. [Epub ahead of print.]
- Geeraert P, Williams JS, Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. *J Drugs Dermatol*. 2013;12(5):519-523.
- Cakir BO, Adamson P, Cingi C. Epidemiology and economic burden of non-melanoma skin cancer. *Facial Plast Surg Clin North Am*. 2012;20(4):419-422.
- Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. *Curr Opin Oncol*. 2013;25(3):218-223.
- Fellner C. Vismodegib (Erivedge) for advanced basal cell carcinoma. *P T*. 2012;37(12):670-682.
- Fecher LA. Systemic therapy for inoperable and metastatic basal cell cancer. *Curr Treat Options Oncol*. 2013;14(2):237-248.
- Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. *N Engl J Med*. 2005;353(21):2262-2269.
- Asilian A, Tamizifar B. Aggressive and neglected basal cell carcinoma. *Dermatol Surg*. 2005;31(11 Pt 1):1468-1471.
- Lam C, Ou JC, Billingsley EM. "PTCH"-ing It Together: A Basal Cell Nevus Syndrome Review. *Dermatol Surg*. 2013 May 31. [Epub ahead of print.]
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med*. 2012;366(23):2180-2188.
- Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. *JAMA Dermatol*. 2013;149(5):639-641.
- Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. *Arch Dermatol*. 2012;148(11):1324-1325.
- Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. *JAMA Dermatol*. 2013;149(2):242-243.
- Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. *Semin Cutan Med Surg*. 2012;31(4):204-210.
- Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. *Clin Ther*. 2012;34(10):2039-2050.
- Shah M, Mavers M, Bree A, Fosko S, Lents NH. Quality of life and depression assessment in nevus basal cell carcinoma syndrome. *Int J Dermatol*. 2011;50(3):268-276.

## AUTHOR CORRESPONDENCE

**Panta Rouhani Schaffer MD PhD MPH**

E-mail:.....panta.rouhani@nyumc.org

# Vismodegib: A Hedgehog Pathway Inhibitor for Locally Advanced and Metastatic Basal Cell Carcinomas

Joesph F. Sobanko MD,<sup>a</sup> Jonathan Okman BA MBA,<sup>b</sup> and Christopher Miller MD<sup>a</sup>

<sup>a</sup>Division of Dermatologic Surgery and Cutaneous Oncology, University of Pennsylvania, Philadelphia, PA

<sup>b</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

## ABSTRACT

Basal cell carcinomas (BCCs) are the most common cancer in the United States, and the overwhelming majority of BCCs are the result of hedgehog pathway activation. While locally advanced and metastatic BCC are rare, currently available treatments remain limited and are often unsuccessful. Vismodegib inhibits a key regulatory protein in the hedgehog pathway and was approved by the United States Food and Drug Administration in 2012. This orally-administered medication offers a novel approach for treating locally advanced and metastatic BCC. The following review will address vismodegib's mechanism of action, published clinical trial data, and the questions that still remain unanswered about this new medication.

*J Drugs Dermatol.* 2013;12(suppl 10):s154-s155.

## INTRODUCTION

Approximately 2.8 million basal cell carcinomas (BCCs) occur in the United States each year, accounting for 80% of all non-melanoma skin cancers (NMSC); but fewer than 1,000 patients will die every year from BCC.<sup>1,2</sup> Effective surgical and destructive modalities allow for successful removal of the overwhelming majority of BCCs.<sup>3</sup> However, 0.5% of BCCs evade surgical control because of either advanced local growth or metastasis.<sup>4</sup> Systemic treatment with traditional chemotherapy offers mild improvement in progression-free survival and cure rates, with median survival times from diagnosis ranging from 6 months to 3.6 years.<sup>5,6</sup> A novel class of systemic medicines targeting the hedgehog (Hh) pathway may improve outcomes for patients with inoperable locally advanced or metastatic BCC.

The Hh pathway consists of a series of membrane and intracellular proteins that regulate cell proliferation and is of particular importance in BCC pathogenesis. During embryogenesis, Hh gene activation directs the orientation of body segments and initiates development of the limb buds and neural tube.<sup>7,8</sup> In adults, this pathway is typically inactive. An encoded transmembrane receptor (patched homologue [PTCH] 1) binds and inhibits smoothened (SMO), another transmembrane protein, preventing it from initiating a downstream intracellular pathway that eventually leads to transcription of the glioma-associated oncogene (GLI)1 and GLI2. Transcription of GLI1 and GLI2, zinc finger domain transcription factors, leads to increased expression of proteins essential for cell proliferation. When the Hh ligand binds to PTCH, PTCH releases its inhibition on SMO, leading to activation of the signaling cascade.

The Hh pathway is mutated and constitutively active in 90% of sporadic BCCs.<sup>9,10,11</sup> Patients with nevoid basal cell carcinoma syndrome (NBCCS) possess an inherited, inactivating mutation and loss of heterozygosity in PTCH1.<sup>12,13</sup> Patched homologue 1 mutations may lead to BCC formation by preventing the protein's normal inhibition of the SMO receptor. Without inhibition,

the SMO receptor initiates the Hh pathway signaling cascade, GLI1 gene transcription and, ultimately, cell proliferation. Less frequently, a mutated smoothened receptor may act as an oncogene, constitutively activating the Hh pathway.<sup>11,14</sup>

## Hedgehog Pathway Inhibition With Vismodegib

Vismodegib, a small-molecule inhibitor of the Hh pathway, was first approved by the United States Food and Drug Administration in January 2012 for locally-advanced and metastatic BCCs. This orally-administered medication inhibits SMO signal transduction and prevents nuclear localization of GLI1 transcription factors. Clinical trials of this medication reveal response rates between 30% and 60% for locally advanced and metastatic BCCs.<sup>15,16</sup> In patients with NBCCS, vismodegib also reduces the number of new and already-present surgically-eligible BCCs.<sup>17</sup>

In 2 of the largest published clinical trials, enrolled patients were categorized as metastatic BCC or locally-advanced BCC. This latter category included patients who had inoperable disease or were not appropriate surgical candidates, because of multiple recurrences and a low likelihood of surgical cure or the anticipation of substantial disfigurement. In the phase 2 study, patients received 150 mg of vismodegib daily until disease progression, unacceptable toxic effects, or discontinuation of the study.<sup>16</sup> The median duration of therapy for these trials was 9.8 months and 7.6 months, respectively. In neither study did a patient with metastatic BCC have a complete response to vismodegib; however, 50% and 30% of metastatic BCC patients did experience a partial response. An objective response was defined with the Response Evaluation Criteria in Solid Tumors (RECIST) in patients with metastatic BCC. In locally advanced BCCs, an objective response was defined as a decrease of 30% or more in the externally visible or radiologic dimension or complete resolution of ulceration (if present at baseline). In patients with locally-advanced BCC, 13% and 21% of patients experienced a complete response (absence of residual

BCC in a biopsy specimen), while 47% and 22% experienced a partial response with vismodegib.<sup>15,16</sup>

### Questions That Still Remain

While early data appear promising, there is still much to be determined regarding vismodegib's role in BCC treatment. First, the category of "inoperable" BCC is rather subjective and must be better developed. Many recurrent BCCs that are considered inoperable by one surgeon may be deemed surgically appropriate by another surgeon. This decision has significant financial implications too, because the cost of 10 months of vismodegib is \$75,000 compared with less than \$2,000 for the surgical treatment of most BCCs.<sup>18,19</sup>

Second, vismodegib may not offer better results than chemotherapeutic agents currently used for metastatic BCCs. Cisplatin-containing regimens have been associated with overall response rates of up to 77%, including complete response rates of up to 45%.<sup>20-23</sup> Neutropenia and renal toxicity are feared adverse events (AEs) of cytotoxic cisplatin-based regimens; however, the side effects from vismodegib frequently result in medication termination.<sup>24</sup> Twenty-seven percent of NBCCS patients at 8 months and 54% of patients at 18 months discontinued their medication because of side-effect intolerability.<sup>17</sup> The most frequently reported AEs are muscle spasms, dysgeusia, weight loss, fatigue, nausea, diarrhea, and alopecia.<sup>15,16,24</sup>

Finally, the proper duration of vismodegib therapy must be determined. It appears that BCCs and other tumors that involve the Hh pathway develop resistance to vismodegib with subsequent disease progression.<sup>25,26,27</sup> This may be the result of a missense mutation in the SMO receptor that decreases vismodegib's affinity for the receptor. Additionally, the rebound of BCCs after vismodegib cessation have been reported in one patient.<sup>28</sup> Future avenues of research that warrant further investigation include the use of vismodegib as a neoadjuvant medication prior to surgical resection.<sup>29</sup> Other medications such as such as itraconazole and arsenic trioxide may also offer promising results for vismodegib-resistant BCCs that acquire SMO mutations.<sup>30</sup>

### DISCLOSURES

The authors have no relevant conflicts of interest to disclose.

### REFERENCES

1. National Cancer Institute. Available at: <http://www.cancer.gov/cancertopics/types/skin>. Accessed August 26, 2013.
2. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of non-melanoma skin cancer in the United States, 2006. *Arch Dermatol*. 2010;146(3):283-287.
3. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. *J Invest Dermatol*. 2013;133(5):1188-1196.
4. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. *J Am Acad Dermatol*. 1984;10(6):1043-1060.
5. Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. *J Skin Cancer*. 2011;650258.
6. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. *Cancer Metastasis Rev*. 2004;23(3-4):389-402.
7. Evangelista M, Tian H, de Sauvage FJ. The hedgehog signaling pathway in cancer. *Clin Cancer Res*. 2006;12(20 Pt 1):5924-5928.
8. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in *Drosophila*. *Nature*. 1980;287(5785):795-801.
9. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. *J Invest Dermatol*. 1998;110(6):885-888.
10. Wolter M, Reifemberger J, Sommer C, Ruzicka T, Reifemberger G. Mutations in the human homologue of the *Drosophila* segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. *Cancer Res*. 1997;57(13):2581-2585.
11. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. *Nature*. 1998;391(6662):90-92.
12. Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell*. 1996;85(6):841-851.
13. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science*. 1996;272(5268):1668-1671.
14. Reifemberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. *Br J Dermatol*. 2005;152(1):43-51.
15. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med*. 2009;361(12):1164-1172.
16. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med*. 2012;366(23):2171-2179.
17. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med*. 2012;366(23):2180-2188.
18. The Pharma Letter. Faster-than-expected FDA approval of Roche's vismodegib. Available at: <http://thepharmaletter.com/file/110669/faster-than-expected-fda-approval-of-roches-vismodegib.html>. Accessed August 26, 2013.
19. Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. *Cochrane Database Syst Rev*. 2012;2:CD007041.
20. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. *Eur J Cancer*. 1990;26(1):73-77.
21. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. *ANZ J Surg*. 2004;74(8):704-705.
22. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma—a review of the literature. *Acta Oncol*. 1996;35(6):677-682.
23. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. *Cancer Invest*. 2006;24(4):396-400.
24. Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer. *Am J Health Syst Pharm*. 2013;70(12):1033-1038.
25. Genentech Inc. Erivedge™ Prescribing Information. 2012. Available at: [http://www.gene.com/download/pdf/erivedge\\_prescribing.pdf](http://www.gene.com/download/pdf/erivedge_prescribing.pdf). Accessed August 26, 2013.
26. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med*. 2009;361(12):1173-1178.
27. Yauch RL, Dijkgraaf GJ, Aliche B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. *Science*. 2009;326(5952):572-574.
28. Geeraert P, Williams JS, Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. *J Drugs Dermatol*. 2013;12(5):519-523.
29. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. *Dermatol Surg*. 2012;38(11):1863-1866.
30. Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. *JAMA Dermatol*. 2013;149(5):639-641.
31. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. *Cancer Cell*. 2013;23(1):23-34.

### AUTHOR CORRESPONDENCE

Joesph F. Sobanko MD

E-mail:.....joseph.sobanko@uphs.upenn.edu

**CME Post-Test: For fastest results, please complete this activity online by scanning the QR code below or visiting [www.JDDonline.com](http://www.JDDonline.com)** in the Medical Education Library, where you will be able to receive your CME certificate immediately upon achieving the passing score. Successful completion of the Post-Test is required to earn *AMA PRA Category 1 Credits™*. You must earn a passing score of at least 70% and complete the activity evaluation form in order to complete the course, and receive a certificate for *AMA PRA Category 1 Credits™*. You can take the test online as many times as you require to achieve the passing score. Alternatively, you may select your best answer for each of the following questions and insert them into the Answer Grid found on the Evaluation/Certificate Request Form on page s157, and return your completed Evaluation/Certificate Request Form to JDD by fax to (718) 407-0898, or by mail to 377 Park Avenue South, 6th Floor, New York, NY 10016.



1. Vismodegib is approved for the treatment of:
  - a. Metastatic basal cell carcinoma
  - b. Basal cell carcinoma that is greater than 10 mm in size
  - c. Basal cell carcinoma that not operable because of anatomic or cosmetic structures in the area
  - d. All of the above
2. Vismodegib works by:
  - a. Inhibiting the hedgehog pathway.
  - b. Inhibiting replication of basal cell carcinoma cells based on inhibition of DNA synthase
  - c. Amplification of BRAF proteins
  - d. Stimulation of toll-like receptors
3. Among the most common adverse events associated with the use of vismodegib are the following:
  - a. Dysgeusia
  - b. Loss of vision
  - c. Fatigue
  - d. a and c
4. Advanced basal cell carcinoma may be defined as all of the following EXCEPT:
  - a. Inoperable basal cell carcinoma due to size or anatomic location of lesion
  - b. Metastatic basal cell carcinoma
  - c. Inoperable basal cell carcinoma due to patient's age, comorbidities, and/or overall health status
  - d. Localized superficial basal cell carcinoma
  - e. Locally advanced basal cell carcinoma
5. Characteristics of high risk basal cell carcinomas include:
  - a. Location on central face or ears
  - b. Diameter greater than 2 cm in size
  - c. Perivascular or perineural spread
  - d. A history of radiation exposure
  - e. All of the above
6. The classical clinical triad of basal cell nevus syndrome includes:
  - a. Palmoplantar pits, sternal clefting, and frontal bossing
  - b. Multiple basal cell carcinomas, jaw keratocysts, and bifid rib
7. BCNS is due to a mutation of the \_\_\_\_\_ pathway:
  - a. Ras-Raf
  - b. Sonic hedgehog
  - c. Wnt/ $\beta$ -catenin
  - d. BRAF
  - e. Mismatch repair
8. Vismodegib targets which of the following receptors:
  - a. Nuclear membrane bound transcription receptor GLI1
  - b. Tyrosine kinase transmembrane receptor
  - c. PTCH1 transmembrane receptor
  - d. Smoothened transmembrane receptor
  - e. Cytoplasmic steroid receptor
9. During normal adult life, the hedgehog pathway is:
  - a. Largely inactivated, except for times of cell proliferation
  - b. Essential to normal epithelial differentiation
  - c. Critical to maintain immune system tolerance
  - d. Key to DNA repair activities
10. The most common hedgehog pathway mutation found in sporadic basal cell carcinomas leads directly to:
  - a. Increased affinity for Hh ligand
  - b. Inactivated PTCH1
  - c. Decreased smoothened activity
  - d. Increased tyrosine kinase phosphorylation
  - e. Hyperactive JAK/STAT signaling
11. Phase 1 and 2 trials of vismodegib in advanced basal cell carcinoma demonstrated response rates of approximately:
  - a. 10%-15%
  - b. 25%
  - c. 30%-60%
  - d. 50%-80%



# Evaluation Form

## ADVANCED BASAL CELL CARCINOMA: THERAPEUTIC OPTIONS AND CONSIDERATIONS FOR PATIENT CARE

To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation/Certificate Form. **For fastest results, please complete this form online at JDDonline.com** in the Medical Education Library. **You must complete and submit this form or complete the CME activity online to receive credit for completing this activity. There is no fee for this CME activity.** You must earn a passing score of at least 70% and complete the activity evaluation form in order to complete the course and receive a certificate for *AMA PRA Category 1 Credits™*. Alternatively, you may return this form to JDD by fax to (718) 407-0898, or by mail to 377 Park Avenue South, 6th Floor, NY, NY 10016.

### Request for Credit

Name	Degree	
Organization	Specialty	
Address		
City	State	ZIP
Telephone	Fax	
Email		
Signature	Date	

I am registered on JDDonline.com  
☐ Yes ☐ No

If yes:  
 User Name Password

### Post-test Answer Key

1	2	3	4	5	6	7	8	9

☐ I certify my actual time spent to complete this educational activity to be: \_\_\_\_\_

☐ I participated in the entire activity and claim 1 *AMA PRA Category 1 Credit™*.

### Please answer the following questions by circling the appropriate rating:

1 = Strongly Disagree	2 = Disagree	3 = Neutral	4 = Agree	5 = Strongly Agree
-----------------------	--------------	-------------	-----------	--------------------

#### Was timely and will influence how I practice

1 2 3 4 5

#### Enhanced my current knowledge base

1 2 3 4 5

#### Addressed my most pressing questions

1 2 3 4 5

#### Provided new ideas or information I expect to use

1 2 3 4 5

#### Addressed competencies identified by my specialty

1 2 3 4 5

#### Avoided commercial bias or influence

1 2 3 4 5

#### Impact of the Activity

Name one new strategy you learned as a result of completing this activity:

Name one thing you intend to change in your practice as a result of completing this activity:

Additional comments about this activity:

Please list any topics you would like to see addressed in future educational activities:





